What Is Retatrutide?

Research Background

Retatrutide is designed to act on three different hormone-signalling pathways at once, known as GLP-1, GIP, and glucagon. Earlier compounds in this field work on one or two of these pathways — GLP-1 only, or GLP-1 and GIP together, as with Tirzepatide. Retatrutide adds a third, which is why it's often described as a "triple agonist."

The idea behind combining three pathways is fairly simple. Each one plays a different role in how the body regulates weight, appetite, and blood sugar, so engaging all three together is one way researchers are exploring whether a broader combined effect is possible. Retatrutide remains an investigational compound. It has not been approved for medical use anywhere, and everything published about it so far comes from laboratory and clinical research, not real-world treatment.

Mechanism Investigated

Each of the three pathways plays a different role. GLP-1 is linked to insulin release, digestion speed, and appetite signals in the brain. GIP is linked to insulin release too, and — in more recent research — to how the body handles fat tissue, an area still less well understood than GLP-1. Glucagon is the unusual one to include, since it's normally associated with the opposite effect: raising blood sugar and energy use, rather than lowering it.

Researchers are interested in Retatrutide specifically because it engages all three pathways at once, rather than just one or two. Much of the mechanistic research to date has focused on how these three signals interact when combined, rather than looking at any single pathway in isolation. This kind of work happens at the laboratory level first — using receptor-binding assays and cell-based studies — well before any research in living organisms takes place.

Published Research

Early laboratory research on Retatrutide was published by Coskun et al. in Cell Metabolism (2022), describing how the compound binds to and activates the three receptor pathways in cell and animal studies. This established the scientific basis for later human research, though animal findings don't automatically apply to humans.

The first major human trial was a Phase 2 study published by Jastreboff et al. in the New England Journal of Medicine (2023), which followed adult participants over 48 weeks at several dose levels. Since then, a Phase 3 programme has been completed, with results reported across several trials in 2025 and 2026, each meeting its primary study goal and describing further reductions in body weight among participants at higher doses. As of this writing, these results have been announced but not yet fully published in a peer-reviewed journal, and Retatrutide has not received regulatory approval from the FDA, EMA, or any other authority. A regulatory submission is anticipated but has not yet occurred.

Limitations

Retatrutide has moved further through the research pipeline than many compounds discussed on this site. It now has both laboratory and clinical data behind it, including a completed Phase 3 programme. Even so, it remains an investigational compound. It has not been approved for medical use anywhere, and the most recent trial results have been announced but not yet fully published in a peer-reviewed journal. As with much peptide research, results can vary between studies and are not always independently replicated straight away. Readers should treat everything covered here as an active area of research, not a settled, established conclusion.